Matrix tablets based on a carrageenan with the modified-release of sodium riboflavin 50-phosphate

Gyula Buchholcz, András Kelemen, Tamás Sovány, K. Pintye-Hódi

Research output: Contribution to journalArticle

1 Citation (Scopus)


The focus of this work was to produce modified-release monolithic matrix tablets containing sodium riboflavin 5'-phosphate (Vitamin B2) as active pharmaceutical ingredient (API). Riboflavin 5'-phosphate is absorbed from the upper gastrointestinal tract by a specific transport mechanism. The aim of this work was the development of modified-release tablets from which most or the entire API can dissolve within 5 h. The dissolution was started in medium pH 1.2 (gastric juice) and finished in medium pH 4.5. The matrix former was iotacarrageenan combined with microcrystalline cellulose (MCC) and lactose in different ratios. Factorial design was used in this work so as to study the effects of the MCC/lactose ratio on the parameters of the tablets, and especially on the dissolution process. The dissolution data were subjected to statistical analysis, and the release profiles were fitted with different models. It was found that the MCC/lactose ratio influenced the quality of the tablets to a high degree. The Korsmeyer-Peppas model proved to characterize the total dissolution profile best, but fitting of the separate sections was also possible with a linear model.

Original languageEnglish
Pages (from-to)676-683
Number of pages8
JournalPharmaceutical Development and Technology
Issue number6
Publication statusPublished - Jan 1 2015



  • Factorial design
  • Iota-carrageenan
  • Monolithic matrix tablet
  • Statistical analysis

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this